US Patent Issued to Regeneron Pharmaceuticals on May 20 for "Factor XI A2 domain-binding antibodies and methods of use thereof" (New York, Pennsylvania Inventors)

ALEXANDRIA, Va., June 16 -- United States Patent no. 12,304,969, issued on May 20, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Factor XI A2 domain-binding antibodies and methods of use thereof" was invented by Dan Chalothorn (New York), Lori C. Morton (Chappaqua, N.Y.) and KehDih Lai (Yardley, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides antibodies that bind to the A2 domain of Factor XI (FXI) and methods of using the same. According to certain embodiments, the antibodies are antagonist antibodies that inhibit blood clot formation via the intrinsic pathway without affecting hemostasis, as shown by their effect on prolonging aPTT without affecting P...